PLANEGG-MARTINSRIED, Germany--(BUSINESS WIRE)--4SC (Frankfurt, Prime Standard: VSC), a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany. These data include an overview on the clinical development activities of the pan-HDAC inhibitor resminostat, currently in Phase II trials in hepatocellular cancer and Hodgkin’s lymphoma, a profile of its second, selective-HDAC inhibitor 4SC-202 and an introduction to 4SC-207, an anti-mitotic cell cycle blocker.
